AstraZeneca Annual Report and Form 20-F Information 2011

More documents

Recommendations

Info

Development PipelineNCEsPhase III/RegistrationDateEstimated FilingCompound Mechanism Area Under Investigation PhaseCommencedPhase US EU Japan EmergingCardiovascularBrilinta/Brilique ADP receptor antagonist arterial thrombosis III Launched Launched 1H 2013 Launcheddapagliflozin # SGLT2 inhibitor diabetes III 3Q 2007 Filed* Filed 1H 2013 FiledInfectionCAZ AVI # (CAZ104) beta lactamase inhibitor/ serious infections III** 1Q 2012 2014 2014 2014cephalosporinQ-LAIV Flu Vac*** live, attenuated, intranasal seasonal influenza III 1Q 2009 Filed 4Q 2012(MEDI-3250)influenza virus vaccine(quadrivalent)Zinforo # (ceftaroline) extended spectrumpneumonia/skin infections III 1Q 2007 Filed Filedcephalosporin with affinity topenicillin-binding proteinsNeuroscienceNKTR-118 #TC-5214 #oral peripherally-acting opioidantagonistneuronal nicotinic channelmodulatorOncologyCaprelsa(vandetanib)Ranmark TM #anti-RANKL MAb(denosumab)Respiratory & Inflammationfostamatinib #opioid-inducedconstipationmajor depressive disorder(adjunct)III 2Q 2011**** 2H 2013 2H 2013III 2Q 2010 3Q 2012 2015VEGFR/EGFR tyrosine kinase medullary thyroid cancer III Launched Filed 2014 Filedinhibitor with RET kinase activityspleen tyrosine kinase (SYK)inhibitorbone disorders stemmingfrom bone metastasis#Partnered product.* CRL received in January 2012. See page 61 of the Therapy Area Review for more information.** Phase III dosing expected in 1Q 2012.*** supplemental Biologics License Application (sBLA) in US, MAA in EU.**** Enrolment began in 1Q 2011.IIIApprovedrheumatoid arthritis III 3Q 2010 2H 2013 2H 2013 2H 2013200 Development PipelineAstraZeneca Annual Report and Form 20-F Information 2011
NCEsPhases I and IICompound Mechanism Area Under Investigation PhaseDateCommencedPhaseCardiovascularAZD2927 ion channel blocker/inhibitor atrial fibrillation II 4Q 2011AZD4017 11BHSD glaucoma II 1Q 2011AZD2820 #melanocortin receptor type obesity I 2Q 20114(MC4r) partial agonist peptideGastrointestinaltralokinumab (CAT-354) anti-IL-13 MAb ulcerative colitis I 2Q 2011InfectionAZD9773 #anti-TNF-alpha polyclonal severe sepsis II 1Q 2008antibodyCXL # (CEF104)beta lactamase inhibitor/ MRSA II 4Q 2010cephalosporinAZD5099 gyrase B serious infections I 2Q 2011AZD5847oxazolidinone antibacterial tuberculosis I 4Q 2009inhibitorMEDI-534 RSV/PIV-3 vaccine RSV/PIV prophylaxis I 2Q 2005MEDI-550 pandemic influenza virus vaccine pandemic influenza prophylaxis I 2Q 2006MEDI-557 anti-RSV MAb –extended half-lifeRSV prevention in high-riskadults (COPD/CHF/other) I 3Q 2007MEDI-559 paediatric RSV vaccine RSV prophylaxis I 4Q 2008NeuroscienceAZD2423 CCR2b antagonist chronic neuropathic pain II 4Q 2010AZD3480 #alpha4/beta2 neuronal nicotinic Alzheimer’s disease II 3Q 2007receptor agonistAZD6765 NMDA receptor antagonist major depressive disorder II 3Q 2007TC-5214 #neuronal nicotinic channel major depressive disorder II 1Q 2011modulator(monotherapy)AZD1446 #alpha4/beta2 neuronal nicotinic Alzheimer’s disease I 4Q 2008receptor agonistAZD3241myeloper-oxidase (MPO) Parkinson’s disease I 2Q 2007inhibitorAZD3839 # beta-secretase (BACE) inhibitor Alzheimer’s disease I 3Q 2011AZD5213 histamine-3 receptor antagonist Alzheimer’s disease/ADHD I 2Q 2010MEDI-578 anti-NGF MAb OA pain I 1Q 2010OncologyAZD4547 FGFR tyrosine kinase inhibitor solid tumours II 4Q 2011AZD8931 erbB kinase inhibitor breast cancer chemo. combi./ II 2Q 2010solid tumoursfostamatinib # *spleen tyrosine kinase (SYK) haematological malignancies II 1Q 2012inhibitorMEDI-575 # anti-PDGFR-alpha MAb NSCLC/glioblastoma II 4Q 2010selumetinib # (AZD6244) MEK inhibitor solid tumours II 4Q 2006(ARRY-142886)tremelimumab # anti-CTLA4 MAb solid tumours II 3Q 2004AZD1480 JAK1, 2 inhibitor solid tumours I 2Q 2009AZD2014 TOR kinase inhibitor solid tumours I 1Q 2010AZD3514androgen receptorprostate cancer I 3Q 2010down-regulatorAZD5363 # AKT inhibitor solid tumours I 4Q 2010AZD8330 # (ARRY-424704) MEK inhibitor solid tumours I 1Q 2007MEDI-551 # anti-CD19 MAb haematological malignancies I 2Q 2010MEDI-565 # anti-CEA BiTE solid tumours I 1Q 2011MEDI-573 # anti-IGF MAb solid tumours I 1Q 2009MEDI-3617 # anti-ANG-2 MAb solid tumours I 4Q 2010moxetumomab pasudotox #(CAT-8015)anti-CD22 recombinantimmunotoxinhaematological malignancies I 2Q 2007olaparib PARP inhibitor solid tumours I 4Q 2008selumetinib # (AZD6244) MEK/AKT inhibitor solid tumours I 4Q 2009(ARRY-142886)/MK2206# Partnered product.* Added to pipeline table after starting Phase II in January 2012.Estimated FilingUS EU Japan EmergingAdditional InformationAstraZeneca Annual Report and Form 20-F Information 2011Development Pipeline 201
Page 1 and 2:
healthAstraZeneca Annual Reportand
Page 3 and 4:
Financial summary$33.6bnSales down
Page 5 and 6:
China: We announcedour decision to
Page 7 and 8:
OverviewOperational overview7979 pr
Page 9 and 10:
Chairman’s StatementI would like
Page 11 and 12:
Chief Executive Officer’s ReviewA
Page 13 and 14:
The process of getting a drug to ma
Page 15 and 16:
OverviewnovationInnovation drives p
Page 17 and 18:
Our Strategy and PerformanceMore pe
Page 19 and 20:
Using the full range of innovative
Page 21 and 22:
Our strategyMissionto make the most
Page 23 and 24:
Our strategic priorities to 2014Our
Page 25 and 26:
Our performance in 2011Our performa
Page 27 and 28:
Business shapePeopleResponsible bus
Page 29 and 30:
Strategy and PerformanceaborationIm
Page 31 and 32:
Delivering our strategyOur strategy
Page 33 and 34:
Development projects20112010 129342
Page 35 and 36:
Investing in capabilitiesA core com
Page 37 and 38:
Patent expiries for our key markete
Page 39 and 40:
our Established Markets footprint i
Page 41 and 42:
Product qualityWe are committed to
Page 43 and 44:
We have a global approach, supporte
Page 45 and 46:
ComplianceWe ensure a culture of et
Page 47 and 48:
tegrityBusiness ReviewWe are dedica
Page 49 and 50:
Delivering our strategyResponsible
Page 51 and 52:
India has the fastest growing numbe
Page 53 and 54:
ProtestsAstraZeneca acknowledges th
Page 55 and 56:
Also in 2011, the DIHR in collabora
Page 57 and 58:
healthcollaborationRaising breast c
Page 59 and 60:
Pipeline by Therapy Area at 31 Dece
Page 62 and 63:
Therapy Area ReviewIn September, we
Page 64 and 65:
Therapy Area ReviewGastrointestinal
Page 66 and 67:
Therapy Area ReviewInfectionTherapy
Page 68 and 69:
Therapy Area ReviewIn the pipelineI
Page 70 and 71:
Therapy Area ReviewOur financial pe
Page 72 and 73:
Therapy Area ReviewOncologyTherapy
Page 74 and 75:
Therapy Area Reviewendpoints of pro
Page 76 and 77:
Therapy Area ReviewOur financial pe
Page 78 and 79:
healthinnovationReducing the number
Page 80 and 81:
Geographical ReviewUSAstraZeneca is
Page 82 and 83:
Geographical ReviewEmerging Markets
Page 84 and 85:
Disciplined execution of our strate
Page 86 and 87:
Financial ReviewMeasuring performan
Page 88 and 89:
Financial ReviewResults of operatio
Page 90 and 91:
Financial ReviewFinancial position
Page 92 and 93:
Financial ReviewCapitalisation and
Page 94 and 95:
Financial ReviewResults of operatio
Page 96 and 97:
Financial ReviewSensitivity analysi
Page 98 and 99:
Financial Reviewover the performanc
Page 100 and 101:
healthcollaborationFighting the ris
Page 102 and 103:
Board of Directors and Senior Execu
Page 104 and 105:
Board of Directors and Senior Execu
Page 106 and 107:
Corporate Governance ReportOperatio
Page 108 and 109:
Corporate Governance ReportThe Boar
Page 110 and 111:
Corporate Governance ReportDuring 2
Page 112 and 113:
Corporate Governance ReportBusiness
Page 114 and 115:
Corporate Governance ReportPolitica
Page 116 and 117:
Directors’ Remuneration ReportDav
Page 118 and 119:
Directors’ Remuneration ReportVar
Page 120 and 121:
Directors’ Remuneration ReportAdd
Page 122 and 123:
Directors’ Remuneration ReportSum
Page 124 and 125:
Directors’ Remuneration ReportSum
Page 126 and 127:
Directors’ Remuneration ReportIn
Page 128 and 129:
Directors’ Remuneration ReportPer
Page 130 and 131:
Directors’ Remuneration ReportGai
Page 132 and 133:
RiskManagement reporting and assura
Page 134 and 135:
RiskCommercialisation and business
Page 136 and 137:
RiskCommercialisation and business
Page 138 and 139:
RiskSupply chain and delivery risks
Page 140 and 141:
RiskEconomic and financial risks co
Page 142 and 143:
Financial StatementsPreparation of
Page 144 and 145:
Financial StatementsConsolidated St
Page 146 and 147:
Financial StatementsConsolidated St
Page 148 and 149:
Financial StatementsGroup Accountin
Page 150 and 151:
Financial StatementsProperty, plant
Page 152 and 153: Financial StatementsNotes to the Gr
Page 154 and 155: Financial Statements3 Finance incom
Page 156 and 157: Financial Statements4 Taxation cont
Page 158 and 159: Financial Statements6 Segment infor
Page 160 and 161: Financial Statements9 Intangible as
Page 162 and 163: Financial Statements10 Other invest
Page 164 and 165: Financial Statements15 Financial in
Page 166 and 167: Financial Statements15 Financial in
Page 168 and 169: Financial Statements18 Post-retirem
Page 170 and 171: Financial Statements18 Post-retirem
Page 172 and 173: Financial Statements20 Share capita
Page 174 and 175: Financial Statements23 Financial ri
Page 176 and 177: Financial Statements23 Financial ri
Page 178 and 179: Financial Statements24 Employee cos
Page 184 and 185: Financial Statements25 Commitments
Page 192 and 193: Financial Statements26 LeasesTotal
Page 194 and 195: Financial StatementsIndependent Aud
Page 196 and 197: Financial StatementsCompany Account
Page 198 and 199: Financial Statements4 ReservesShare
Page 200 and 201: Financial StatementsGroup Financial
Page 204 and 205: Development PipelineNCEsPhases I an
Page 206 and 207: Shareholder Information> For shares
Page 208 and 209: Shareholder InformationDocuments on
Page 210 and 211: Corporate InformationHistory and de
Page 212 and 213: GlossaryThe following abbreviations
Page 214 and 215: Index2011 performance summary 23Acc
Page 216: Contact informationRegistered offic
show all

AstraZeneca Annual Report and Form 20-F Information 2011

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?